In Section C, members will get ABBV-744 and oral navitoclax. In Phase D, contributors will acquire ABBV-744 and ruxolitinib. Members will get treatment until eventually disease progression or the participants are unable to tolerate the study drugs. Celastrol was recognized to be a Myb inhibitor that suppressed C/EBPβ exercise and https://claytonaoamz.59bloggers.com/32512389/facts-about-new-advancements-in-brd4-inhibition-therapy-abbv-744-revealed